Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance
Historically, treatment of patients with cancer using chemotherapeutic agents has been
associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable …
associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable …
Liposomal, nanoparticle, and conjugated formulations of anticancer agents
WC Zamboni - Clinical cancer research, 2005 - AACR
Major advances in the use of liposomes, conjugates, nanoparticles, and microspheres as
vehicles delivering pharmacologic agents and enzymes to sites of disease have occurred in …
vehicles delivering pharmacologic agents and enzymes to sites of disease have occurred in …
Concept and clinical evaluation of carrier-mediated anticancer agents
WC Zamboni - The oncologist, 2008 - academic.oup.com
Major advances in the use of carrier vehicles delivering pharmacologic agents and enzymes
to sites of disease have occurred over the past 10 years. This review focuses on the …
to sites of disease have occurred over the past 10 years. This review focuses on the …
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical …
WC Zamboni, AC Gervais, MJ Egorin… - Cancer chemotherapy …, 2004 - Springer
Abstract Purpose SPI-077 and SPI-077 B103 are formulations of cisplatin encapsulated in
pegylated STEALTH liposomes that accumulate in tumors. However, the extent to which …
pegylated STEALTH liposomes that accumulate in tumors. However, the extent to which …
Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin …
Skin cancer is among one of the most common human malignancies wide-spread world-
over with mortality statistics rising continuously at an alarming rate. The increasing …
over with mortality statistics rising continuously at an alarming rate. The increasing …
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts
WC Zamboni, S Strychor, E Joseph, DR Walsh… - Clinical cancer …, 2007 - AACR
Purpose: S-CKD602 is a STEALTH liposomal formulation of CKD-602, a camptothecin
analogue. The cytotoxicity of camptothecin analogues is related to the duration of exposure …
analogue. The cytotoxicity of camptothecin analogues is related to the duration of exposure …
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
Developing nanoparticles to improve the specificity of anticancer agents towards tumor
tissue and to better control drug delivery is a rising strategy in oncology. An increasing …
tissue and to better control drug delivery is a rising strategy in oncology. An increasing …
In vivo microdialysis for PK and PD studies of anticancer drugs
Q Zhou, JM Gallo - The AAPS journal, 2005 - Springer
In vivo microdialysis technique has become one of the major tools to sample endogenous
and exogenous substances in extracellular spaces. As a well-validated sampling technique …
and exogenous substances in extracellular spaces. As a well-validated sampling technique …
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts
MD Walsh, SK Hanna, J Sen, S Rawal, CB Cabral… - Clinical cancer …, 2012 - AACR
Purpose: To evaluate the pharmacokinetics and tissue disposition of macromolecular
camptothecin (CPT) drug conjugate, XMT-1001, and irinotecan (CPT-11) in mice bearing HT …
camptothecin (CPT) drug conjugate, XMT-1001, and irinotecan (CPT-11) in mice bearing HT …
Inter-and intratumoral disposition of platinum in solid tumors after administration of cisplatin
WC Zamboni, AC Gervais, MJ Egorin… - Clinical cancer …, 2002 - AACR
One possible explanation for variable tumor response within a single patient may be related
to delivery of chemotherapeutic agents to the tumors. Microdialysis was used to evaluate …
to delivery of chemotherapeutic agents to the tumors. Microdialysis was used to evaluate …